中国临床药学杂志

参考文献

[1] HOLT R I G, DEVRIES J H, HESS-FISCHL A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J]. Diabetologia,2021, 64(12):2609.

[2]中华医学会糖尿病学分会,中国医师协会内分泌代谢科医师分会,中华医学会内分泌学分会,等.中国1型糖尿病诊治指南（2021版）[J].中华糖尿病杂志, 2022, 14(11):1143.

[3] International Diabetes Federation. IDF Diabetes Atlas 2022 Reports[EB/OL].(2022-11-10)[2023-06-21].https://diabetesatlas.org/.

[4] Diabetes Control and Complications Trial Study Research Group.Intensive diabetes treatment and cardiovascular outcomes in type 1diabetes:the DCCT/EDIC study 30-year follow-up[J]. Diabetes Care, 2016, 39(5):686.

[5] LUDVIGSSON J, FARESJ?M, HJORTH M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes[J]. N Engl J Med, 2008, 359(18):1909.

[6] ORBAN T, BUNDY B, BECKER D J, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1diabetes:a randomised, double-blind, placebo-controlled trial[J].Lancet, 2011, 378(9789):412.

[7] PESCOVITZ M D, GREENBAUM C J, KRAUSE-STEINRAUF H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function[J]. N Engl J Med, 2009, 361(22):2143.

[8] BOUGNèRES P F, LANDAIS P, BOISSON C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin[J].Diabetes, 1990, 39(10):1264.

[9] FDA. FDA Approves First Drug That Can Delay Onset of Type 1Diabetes[A/OL].(2022-11-17)[2023-06-22]. https://www.fda.gov/news-events/press-announcements/fda-approves-firstdrug-can-delay-onset-type-1-diabetes.

[10] XU D, ALEGRE M L, VARGA S S, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies[J].Cell Immunol, 2000, 200(1):16.

[11] ESPOSITO S, TONI G, TASCINI G, et al. Environmental factors associated with type 1 diabetes[J]. Front Endocrinol, 2019, 10:592.

[12] LUO S M, LIN J, XIE Z G, et al. HLA genetic discrepancy between latent autoimmune diabetes in adults and type 1 diabetes:LADA China study No. 6[J]. J Clin Endocrinol Metab, 2016, 101(4):1693.

[13]罗说明,邓敏,杨涛,等.免疫检查点抑制剂诱导的1型糖尿病[J].中华医学杂志, 2020, 100(26):2067.

[14] SHERRY N A, KUSHNER J A, GLANDT M, et al. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1diabetes[J]. Diabetes, 2006, 55(12):3238.

[15] CHATENOUD L, WALDMANN H. CD3 monoclonal antibodies:a first step towards operational immune tolerance in the clinic[J].Rev Diabet Stud, 2012, 9(4):372.

[16] CLEVERS H, ALARCON B, WILEMAN T, et al. The T cell receptor/CD3 complex:a dynamic protein ensemble[J]. Annu Rev Immunol, 1988, 6:629.

[17] SMITH J A, TANG Q, BLUESTONE J A. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets[J]. J Immunol,1998, 160(10):4841.

[18] SMITH J A, TSO J Y, CLARK M R, et al. Nonmitogenic anti-CD3monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy[J]. J Exp Med, 1997, 185(8):1413.

[19] CHATENOUD L, THERVET E, PRIMO J, et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice[J]. Proc Natl Acad Sci USA, 1994, 91(1):123.

[20] BELGHITH M, BLUESTONE J A, BARRIOT S, et al. TGFbeta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes[J].Nat Med, 2003, 9(9):1202.

[21] BISIKIRSKA B, COLGAN J, LUBAN J, et al. TCR stimulation with modified anti-CD3 MAb expands CD8+T cell population and induces CD8+CD25+Tregs[J]. J Clin Invest, 2005, 115(10):2904.

[22] ABLAMUNITS V, BISIKIRSKA B, HEROLD K C. Acquisition of regulatory function by human CD8+T cells treated with anti-CD3antibody requires TNF[J]. Eur J Immunol, 2010, 40(10):2891.

[23] LINSLEY P S, LONG S A. Enforcing the checkpoints:harnessing T-cell exhaustion for therapy of T1D[J]. Curr Opin Endocrinol Diabetes Obes, 2019, 26(4):213.

[24] CERNEA S, HEROLD K C. Monitoring of antigen-specific CD8T cells in patients with type 1 diabetes treated with antiCD3monoclonal antibodies[J]. Clin Immunol, 2010, 134(2):121.

[25] DAIFOTIS A G, KOENIG S, CHATENOUD L, et al. Anti-CD3clinical trials in type 1 diabetes mellitus[J]. Clin Immunol,2013, 149(3):268.

[26] HAGOPIAN W, FERRY R J Jr, SHERRY N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes:two-year results from the randomized, placebo-controlled Protégétrial[J].Diabetes, 2013, 62(11):3901.

[27] HEROLD K C, HAGOPIAN W, AUGER J A, et al. Anti-CD3monoclonal antibody in new-onset type 1 diabetes mellitus[J].N Engl J Med, 2002, 346(22):1692.

[28] HEROLD K C, GITELMAN S E, MASHARANI U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(AlaAla)results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes[J].Diabetes, 2005, 54(6):1763.

[29] HEROLD K C, GITELMAN S, GREENBAUM C, et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 MAb Teplizumab preserves insulin production for up to 5years[J]. Clin Immunol, 2009, 132(2):166.

[30] HEROLD K C, GITELMAN S E, WILLI S M, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period:a randomised controlled trial[J]. Diabetologia, 2013, 56(2):391.

[31] LEBASTCHI J, DENG S Y, LEBASTCHI A H, et al. Immune therapy and β-cell death in type 1 diabetes[J]. Diabetes, 2013,62(5):1676.

[32] HEROLD K C, GITELMAN S E, EHLERS M R, et al. Teplizumab(anti-CD3 MAb)treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial:metabolic and immunologic features at baseline identify a subgroup of responders[J]. Diabetes, 2013, 62(11):3766.

[33] LONG S A, THORPE J, HEROLD K C, et al. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes[J]. Cell Immunol, 2017, 319:3.

[34] PERDIGOTO A L, PRESTON-HURLBURT P, CLARK P, et al. Treatment of type 1 diabetes with teplizumab:clinical and immunological follow-up after 7 years from diagnosis[J].Diabetologia, 2019, 62(4):655.

[35] SHERRY N, HAGOPIAN W, LUDVIGSSON J, et al. Teplizumab for treatment of type 1 diabetes(Protégéstudy):1-year results from a randomised, placebo-controlled trial[J]. Lancet, 2011,378(9790):487.

[36] HEROLD K C, BUNDY B N, LONG S A, et al. An anti-CD3antibody, teplizumab, in relatives at risk for type 1 diabetes[J].N Engl J Med, 2019, 381(7):603.

[37] SIMS E K, CUTHBERTSON D, HEROLD K C, et al. The deterrence of rapid metabolic decline within 3 months after teplizumab treatment in individuals at high risk for type 1 diabetes[J]. Diabetes, 2021, 70(12):2922.

[38] SIMS E K, BUNDY B N, STIER K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals[J]. Sci Transl Med, 2021, 13(583):eabc8980.

[39] MITAL S, NGUYEN H V. Cost effectiveness of teplizumab for prevention of type 1 diabetes among different target patient groups[J]. PharmacoEconomics, 2020, 38(12):1359.

[40] NGUYEN H V, SCHATZ D A, MITAL S, et al. Cost-effectiveness of low-dose antithymocyte globulin versus other immunotherapies for treatment of new-onset type 1 diabetes[J]. Diabetes Technol Ther, 2022, 24(4):258.

[41] ENDPOINT NEWS. Updated:Provention prices drug to delay type I diabetes at193K as FDA nod kicks off US launch with Sanofi[EB/OL].(2022-11-18)[2023-06-22]. https://endpts.com/provention-gets-fda-nod-on-drug-to-delay-type-i-diabetes-kickingoff-us-launch-with-sanofi/